Cargando…

PAX2 Expression in Ovarian Cancer

PAX2 is one of nine PAX genes that regulate tissue development and cellular differentiation in embryos. However, the functional role of PAX2 in ovarian cancer is not known. Twenty-six ovarian cancer cell lines with different histology origins were screened for PAX2 expression. Two ovarian cancer cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Huijuan, Kwan, Suet-Yan, Izaguirre, Daisy I., Zu, Zhifei, Tsang, Yvonne T., Tung, Celestine S., King, Erin R., Mok, Samuel C., Gershenson, David M., Wong, Kwong-Kwok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634442/ https://www.ncbi.nlm.nih.gov/pubmed/23502471 http://dx.doi.org/10.3390/ijms14036090

Ejemplares similares

PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas
por: Tung, Celestine S., et al.
Publicado: (2009)

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
por: Crane, Erin K., et al.
Publicado: (2015)

The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy
por: Izaguirre, Daisy I., et al.
Publicado: (2020)

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells
por: Kwan, Suet-Yan, et al.
Publicado: (2016)

ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells
por: Yeung, Tsz-Lun, et al.
Publicado: (2017)

Pathogenesis and Clinical Management of Uterine Serous Carcinoma
por: Zhang, Li, et al.
Publicado: (2020)

The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary
por: Wong, Kwong-Kwok, et al.
Publicado: (2007)

Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
por: Au Yeung, Chi Lam, et al.
Publicado: (2016)

UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer
por: Hardy, Laura R., et al.
Publicado: (2018)

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum
por: Gershenson, David M, et al.
Publicado: (2015)

Etiology and Pathogenesis of Epithelial Ovarian Cancer
por: Mok, Samuel C., et al.
Publicado: (2007)

PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis
por: Yun, Bo Seong, et al.
Publicado: (2022)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

The PAX8 cistrome in epithelial ovarian cancer
por: Adler, Emily K., et al.
Publicado: (2017)

Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer
por: Corona, Rosario I., et al.
Publicado: (2020)

PAX8 and MECOM are interaction partners driving ovarian cancer
por: Bleu, Melusine, et al.
Publicado: (2021)

PAX2 induces vascular-like structures in normal ovarian cells and ovarian cancer
por: Alwosaibai, Kholoud, et al.
Publicado: (2022)

PAX7, PAX9 and RYK Expression in Cleft Affected Tissue
por: Vaivads, Mārtiņš, et al.
Publicado: (2021)

Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis
por: Ng, Chun Wai, et al.
Publicado: (2022)

A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells
por: Di Palma, Tina, et al.
Publicado: (2014)

Pax2a, but not pax2b, influences cell survival and periocular mesenchyme localization to facilitate zebrafish optic fissure closure
por: Lusk, Sarah, et al.
Publicado: (2021)

Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression
por: Kwan, Suet-Ying, et al.
Publicado: (2020)

PAX8 is a potential marker for the diagnosis of primary epithelial ovarian cancer
por: Chai, Hong-Juan, et al.
Publicado: (2017)

Characterization of Zebrafish Pax1b and Pax9 in Fin Bud Development
por: Chen, Xuemei, et al.
Publicado: (2014)

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
por: Tone, Alicia A, et al.
Publicado: (2014)

Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors
por: Wong, Kwong-Kwok, et al.
Publicado: (2022)

Distinct roles for Pax7 and Pax3 in adult regenerative myogenesis
por: Kuang, Shihuan, et al.
Publicado: (2006)

The regenerative potential of Pax3/Pax7 on skeletal muscle injury
por: Azhar, Muhamad, et al.
Publicado: (2022)

ELISA based quantification of Pax6 expression in the developing Zebrafish embryos
por: Kannan, Rajaretinam R, et al.
Publicado: (2015)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression
por: Yeung, Tsz-Lun, et al.
Publicado: (2018)

Expression of PAX2 and PAX8 in Wilms Tumor: A Tissue Microarray-based Immunohistochemical Study
por: Sefidbakht, Salma, et al.
Publicado: (2021)

The BioPAX Validator
por: Rodchenkov, Igor, et al.
Publicado: (2013)

Pax7 is back
por: Brack, Andrew S
Publicado: (2014)

Differential hRad17 expression by histologic subtype of ovarian cancer
por: Young, Jennifer L, et al.
Publicado: (2011)

Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci
por: Kar, Siddhartha P, et al.
Publicado: (2017)

Pax2 and Pax8 cooperate in mouse inner ear morphogenesis and innervation
por: Bouchard, Maxime, et al.
Publicado: (2010)

Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma
por: de Cristofaro, Tiziana, et al.
Publicado: (2016)

PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming
por: Feng, Yan, et al.
Publicado: (2020)

PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far
por: Di Palma, Tina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p20oktdo51g859nb9ee6vml6vu